NYSE:ZYME Zymeworks (ZYME) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free ZYME Stock Alerts $10.52 +0.22 (+2.14%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$10.34▼$10.5750-Day Range$9.88▼$12.9052-Week Range$6.01▼$13.14Volume468,400 shsAverage Volume572,797 shsMarket Capitalization$742.40 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Get Zymeworks alerts: Email Address Zymeworks MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside28.3% Upside$13.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 3 Articles This WeekInsider TradingSelling Shares$428,174 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.04) to ($0.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.80 out of 5 starsMedical Sector689th out of 938 stocksPharmaceutical Preparations Industry313th out of 423 stocks 3.0 Analyst's Opinion Consensus RatingZymeworks has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.50, Zymeworks has a forecasted upside of 28.3% from its current price of $10.52.Amount of Analyst CoverageZymeworks has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ZYME. Previous Next 0.0 Dividend Strength Dividend YieldZymeworks does not currently pay a dividend.Dividend GrowthZymeworks does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYME. Previous Next 2.9 News and Social Media Coverage News SentimentZymeworks has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Zymeworks this week, compared to 2 articles on an average week.Search Interest9 people have searched for ZYME on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows5 people have added Zymeworks to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zymeworks insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $428,174.00 in company stock.Percentage Held by InsidersOnly 1.22% of the stock of Zymeworks is held by insiders.Percentage Held by Institutions92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zymeworks are expected to grow in the coming year, from ($1.04) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zymeworks is -6.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zymeworks is -6.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZymeworks has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Zymeworks Stock (NYSE:ZYME)Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.Read More ZYME Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZYME Stock News HeadlinesMarch 28, 2024 | finanznachrichten.deZymeworks Inc.: Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of DirectorsMarch 28, 2024 | globenewswire.comZymeworks Announces Appointment of Dr. Neil Gallagher to its Board of DirectorsMarch 29, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…March 27, 2024 | globenewswire.comZymeworks Announces Participation in Upcoming Investor ConferencesMarch 13, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Zymeworks (ZYME), 89bio (ETNB)March 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Zymeworks Amid Positive HERIZON Study Outlook and Robust Commercial Prospects of ZanidatamabMarch 11, 2024 | markets.businessinsider.comHold Rating on Zymeworks Amidst Pipeline Adjustments and Clinical Validation AwaitedMarch 8, 2024 | investorplace.comNext-Gen Winners: 7 Tech Stocks Set to Dominate the DecadeMarch 29, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…March 7, 2024 | finanznachrichten.deZymeworks Inc.: Zymeworks Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | finance.yahoo.comZymeworks Inc. (NYSE:ZYME) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comZymeworks Inc (ZYME) Reports Financial Results for Q4 and Full Year 2023March 7, 2024 | investorplace.comZYME Stock Earnings: Zymeworks Beats EPS, Beats Revenue for Q4 2023March 6, 2024 | seekingalpha.comZymeworks Inc. 2023 Q4 - Results - Earnings Call PresentationMarch 6, 2024 | msn.comZymeworks Q4 2023 Earnings PreviewMarch 6, 2024 | globenewswire.comZymeworks Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 5, 2024 | globenewswire.comZymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual MeetingMarch 5, 2024 | ca.finance.yahoo.comZYME Apr 2024 7.500 callMarch 5, 2024 | ca.finance.yahoo.comZYME Oct 2024 15.000 callMarch 5, 2024 | finance.yahoo.comZYME Mar 2024 20.000 callMarch 5, 2024 | seekingalpha.comZymeworks: A Strong Buy Amidst Zanidatamab's Promising DevelopmentsFebruary 27, 2024 | globenewswire.comZymeworks Announces Participation in Upcoming Investor ConferencesFebruary 22, 2024 | finance.yahoo.comZYME Apr 2024 10.000 putFebruary 22, 2024 | finance.yahoo.comZYME Jul 2024 7.500 putFebruary 22, 2024 | realmoney.thestreet.comShould Investors Get Jazzed Up About This Small-Cap Biotech?February 20, 2024 | investorplace.comLast Call! 7 Small-Cap Stocks Ready to Explode in ValueFebruary 17, 2024 | finance.yahoo.comZYME Mar 2024 15.000 callSee More Headlines Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2021Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:ZYME Previous SymbolNASDAQ:ZYME CUSIPN/A CIK1403752 Webwww.zymeworks.com Phone(302) 274-8744Fax604-737-7077Employees272Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$19.00 Low Stock Price Target$8.00 Potential Upside/Downside+28.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,670,000.00 Net Margins-156.12% Pretax Margin-156.87% Return on Equity-26.20% Return on Assets-20.29% Debt Debt-to-Equity RatioN/A Current Ratio7.41 Quick Ratio7.41 Sales & Book Value Annual Sales$76.01 million Price / Sales9.77 Cash FlowN/A Price / Cash FlowN/A Book Value$6.64 per share Price / Book1.58Miscellaneous Outstanding Shares70,570,000Free Float69,707,000Market Cap$742.40 million OptionableOptionable Beta1.16 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Kenneth H. Galbraith C.A. (Age 61)CEO & Chairman of the Board Comp: $1.04MDr. Christopher Astle Ph.D. (Age 43)Senior VP & CFO Comp: $682.22kDr. Paul Moore Ph.D. (Age 56)Chief Scientific Officer Comp: $872.67kMr. Mark Hollywood (Age 54)Executive VP and Head of Technical & Manufacturing Operations Mr. Daniel Dex J.D.Ph.D., Senior VP, Corporate Secretary & General CounselDiana PapoveSenior Manager of Corporate CommunicationsDr. Lindsey Foulkes B.Sc.Ph.D., Vice President of Corporate DevelopmentMs. Laura O'ConnorHead of Global Human ResourcesDr. Jeffrey Smith M.D.Executive VP & Chief Medical OfficerDr. Josemund Menezes MBBSManaging Director of Early-Stage Development for Asia PacificMore ExecutivesKey CompetitorsBicycle TherapeuticsNASDAQ:BCYCAstria TherapeuticsNASDAQ:ATXSPharming GroupNASDAQ:PHAREnliven TherapeuticsNASDAQ:ELVNLongboard PharmaceuticalsNASDAQ:LBPHView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 10,726 shares on 3/11/2024Ownership: 3.393%Wellington Management Group LLPBought 48,564 shares on 3/5/2024Ownership: 0.293%Goldman Sachs Group Inc.Bought 32,050 shares on 3/1/2024Ownership: 0.287%Perceptive Advisors LLCSold 371,316 shares on 2/26/2024Ownership: 1.535%Price T Rowe Associates Inc. MDBought 1,752 shares on 2/16/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions ZYME Stock Analysis - Frequently Asked Questions Should I buy or sell Zymeworks stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ZYME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYME, but not buy additional shares or sell existing shares. View ZYME analyst ratings or view top-rated stocks. What is Zymeworks' stock price target for 2024? 2 analysts have issued 1 year price targets for Zymeworks' shares. Their ZYME share price targets range from $8.00 to $19.00. On average, they expect the company's stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 28.3% from the stock's current price. View analysts price targets for ZYME or view top-rated stocks among Wall Street analysts. How have ZYME shares performed in 2024? Zymeworks' stock was trading at $10.39 on January 1st, 2024. Since then, ZYME stock has increased by 1.3% and is now trading at $10.52. View the best growth stocks for 2024 here. When is Zymeworks' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ZYME earnings forecast. How were Zymeworks' earnings last quarter? Zymeworks Inc. (NYSE:ZYME) issued its quarterly earnings results on Wednesday, November, 3rd. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.17) by $0.08. The firm earned $4.40 million during the quarter, compared to analysts' expectations of $8.80 million. Zymeworks had a negative trailing twelve-month return on equity of 26.20% and a negative net margin of 156.12%. What ETF holds Zymeworks' stock? Invesco Russell 2000 Dynamic Multifactor ETF holds 148,747 shares of ZYME stock, representing 0.32% of its portfolio. What is Ali Tehrani's approval rating as Zymeworks' CEO? 9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend. What other stocks do shareholders of Zymeworks own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA). When did Zymeworks IPO? Zymeworks (ZYME) raised $65 million in an initial public offering on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager. Who are Zymeworks' major shareholders? Zymeworks' stock is owned by many different retail and institutional investors. Top institutional investors include Rubric Capital Management LP (4.96%), Vanguard Group Inc. (3.42%), Vanguard Group Inc. (3.39%), Perceptive Advisors LLC (1.54%), Granahan Investment Management LLC (1.00%) and Bridgeway Capital Management LLC (0.97%). Insiders that own company stock include Ali Tehrani, Christopher Astle, Ecor1 Capital, Llc, James Priour, Kenneth Galbraith, Neil A Klompas, Neil Josephson and Paul Andrew Moore. View institutional ownership trends. How do I buy shares of Zymeworks? Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ZYME) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.